Aclaris Therapeutics SG&A Expense (Quarterly) Insights

Aclaris Therapeutics Inc (ACRS)

1.175 -0.04 (-3.69%) USD | NASDAQ | May 10, 16:00

1.175 0.00 (0.00%) After-Hours: 18:06

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2014. Upgrade now.

Date	Value
December 31, 2023	8.214M
September 30, 2023	6.798M
June 30, 2023	7.296M
March 31, 2023	8.79M
December 31, 2022	7.146M
September 30, 2022	5.813M
June 30, 2022	6.075M
March 31, 2022	6.099M
December 31, 2021	6.943M
September 30, 2021	5.979M
June 30, 2021	5.87M
March 31, 2021	4.827M
December 31, 2020	4.898M
September 30, 2020	3.859M
June 30, 2020	5.572M
March 31, 2020	6.20M
December 31, 2019	6.056M
September 30, 2019	6.838M
June 30, 2019	7.469M

Date	Value
March 31, 2019	7.464M
December 31, 2018	6.691M
September 30, 2018	6.204M
June 30, 2018	18.99M
March 31, 2018	17.49M
December 31, 2017	-1.578M
September 30, 2017	8.123M
June 30, 2017	6.33M
March 31, 2017	5.158M
December 31, 2016	4.384M
September 30, 2016	3.65M
June 30, 2016	3.153M
March 31, 2016	3.604M
December 31, 2015	2.40M
September 30, 2015	1.233M
June 30, 2015	0.803M
March 31, 2015	0.892M
December 31, 2014	0.548M
September 30, 2014	0.565M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

3.859M

Minimum

Sep 2020

8.79M

Maximum

Mar 2023

6.355M

Average

6.099M

Median

Mar 2022

SG&A Expense (Quarterly) Benchmarks